| Intrexon Corporation engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Walsh Robert F. III | SVP, Energy & Fine Chem. | Jul 01 | Sale | 7.76 | 5,007 | 38,854 | 28,816 | Jul 02 07:13 PM | | Sabzevari Helen | President, Precigen, Inc. | Jul 01 | Sale | 7.76 | 4,822 | 37,419 | 45,825 | Jul 02 07:12 PM | | Sterling Rick L. | Chief Financial Officer | Jul 01 | Sale | 7.76 | 4,359 | 33,826 | 104,629 | Jul 02 07:13 PM | | Perez Jeffrey Thomas | SVP, IP Affairs | Jul 01 | Sale | 7.76 | 4,359 | 33,826 | 42,545 | Jul 02 07:11 PM | | Reed Thomas D. | Chief Science Officer | Jul 01 | Sale | 7.76 | 3,527 | 27,370 | 107,094 | Jul 02 07:12 PM | | Bostick Thomas | Chief Operating Officer | Jul 01 | Sale | 7.76 | 4,359 | 33,826 | 35,877 | Jul 02 07:10 PM | | Lehr Donald P. | Chief Legal Officer | Jul 01 | Sale | 7.76 | 4,822 | 37,419 | 57,476 | Jul 02 07:11 PM | | KIRK RANDAL J | Chief Executive Officer | Jun 07 | Buy | 5.26 | 222,355 | 1,169,587 | 18,268,451 | Jun 10 05:19 PM | | KIRK RANDAL J | Chief Executive Officer | Jun 07 | Buy | 5.26 | 148,237 | 779,727 | 1,142,758 | Jun 10 05:20 PM | | KIRK RANDAL J | Chief Executive Officer | Jun 06 | Buy | 5.23 | 173,942 | 909,717 | 1,113,111 | Jun 10 05:20 PM | | KIRK RANDAL J | Chief Executive Officer | Jun 06 | Buy | 5.23 | 260,913 | 1,364,575 | 18,138,648 | Jun 10 05:19 PM | | KIRK RANDAL J | Chief Executive Officer | Jun 04 | Buy | 5.17 | 45,120 | 233,270 | 1,078,323 | Jun 04 06:05 PM | | KIRK RANDAL J | Chief Executive Officer | Jun 04 | Buy | 5.17 | 67,679 | 349,900 | 17,986,337 | Jun 04 06:01 PM | | KIRK RANDAL J | Chief Executive Officer | May 31 | Buy | 4.78 | 135,642 | 648,369 | 17,902,546 | Jun 04 06:01 PM | | KIRK RANDAL J | Chief Executive Officer | May 31 | Buy | 4.78 | 90,428 | 432,246 | 1,069,299 | Jun 04 06:05 PM | | KIRK RANDAL J | Chief Executive Officer | May 30 | Buy | 4.79 | 307,592 | 1,473,366 | 17,823,362 | May 30 07:42 PM | | KIRK RANDAL J | Chief Executive Officer | May 30 | Buy | 4.79 | 205,060 | 982,237 | 1,051,213 | May 30 07:47 PM | | KIRK RANDAL J | Chief Executive Officer | May 29 | Buy | 4.68 | 125,120 | 585,562 | 1,010,201 | May 30 07:47 PM | | KIRK RANDAL J | Chief Executive Officer | May 29 | Buy | 4.68 | 187,679 | 878,338 | 17,643,801 | May 30 07:42 PM | | KIRK RANDAL J | Chief Executive Officer | May 24 | Buy | 4.68 | 72,430 | 338,972 | 985,177 | May 24 07:29 PM | | KIRK RANDAL J | Chief Executive Officer | May 24 | Buy | 4.68 | 108,645 | 508,459 | 17,534,241 | May 24 07:23 PM | | KIRK RANDAL J | Chief Executive Officer | May 23 | Buy | 4.67 | 128,626 | 600,683 | 17,470,818 | May 24 07:23 PM | | KIRK RANDAL J | Chief Executive Officer | May 23 | Buy | 4.67 | 85,750 | 400,453 | 970,691 | May 24 07:29 PM | | KIRK RANDAL J | Chief Executive Officer | May 22 | Buy | 4.70 | 115,187 | 541,379 | 953,541 | May 24 07:29 PM | | KIRK RANDAL J | Chief Executive Officer | May 22 | Buy | 4.70 | 172,779 | 812,061 | 17,395,730 | May 24 07:23 PM | | KIRK RANDAL J | Chief Executive Officer | May 21 | Buy | 4.74 | 60,223 | 285,457 | 930,504 | May 21 08:07 PM | | KIRK RANDAL J | Chief Executive Officer | May 21 | Buy | 4.74 | 90,335 | 428,188 | 17,294,866 | May 21 08:05 PM | | KIRK RANDAL J | Chief Executive Officer | May 20 | Buy | 4.63 | 452,502 | 2,095,084 | 17,242,131 | May 21 08:05 PM | | KIRK RANDAL J | Chief Executive Officer | May 20 | Buy | 4.63 | 301,670 | 1,396,732 | 918,459 | May 21 08:07 PM | | KIRK RANDAL J | Chief Executive Officer | May 17 | Buy | 4.69 | 60,530 | 283,886 | 858,125 | May 21 08:07 PM | | KIRK RANDAL J | Chief Executive Officer | May 17 | Buy | 4.69 | 90,794 | 425,824 | 16,977,975 | May 21 08:05 PM | | KIRK RANDAL J | Chief Executive Officer | May 15 | Buy | 4.59 | 471,077 | 2,162,243 | 16,924,973 | May 15 05:36 PM | | KIRK RANDAL J | Chief Executive Officer | May 15 | Buy | 4.59 | 314,050 | 1,441,490 | 846,019 | May 15 05:38 PM | | KIRK RANDAL J | Chief Executive Officer | May 14 | Buy | 4.37 | 147,500 | 644,575 | 783,209 | May 15 05:38 PM | | KIRK RANDAL J | Chief Executive Officer | May 14 | Buy | 4.37 | 221,251 | 966,867 | 16,649,972 | May 15 05:36 PM | | KIRK RANDAL J | Chief Executive Officer | May 13 | Buy | 4.25 | 565,399 | 2,402,946 | 16,520,814 | May 15 05:36 PM | | KIRK RANDAL J | Chief Executive Officer | May 13 | Buy | 4.25 | 376,932 | 1,601,961 | 753,709 | May 15 05:38 PM | | KIRK RANDAL J | 10% Owner | Apr 03 | Sale | 0.65 | 95,241 | 61,907 | 62,342 | Apr 03 05:13 PM | | KIRK RANDAL J | 10% Owner | Apr 02 | Sale | 0.66 | 13,646 | 9,006 | 88,422 | Apr 03 05:13 PM | | KIRK RANDAL J | 10% Owner | Apr 01 | Sale | 0.67 | 41,678 | 27,924 | 92,159 | Apr 03 05:13 PM | | MITCHELL DEAN J | Director | Mar 12 | Option Exercise | 3.17 | 8,906 | 28,232 | 41,750 | Mar 12 07:11 PM | | Reed Thomas D. | Chief Science Officer | Mar 05 | Sale | 4.66 | 2,300 | 10,718 | 41,705 | Mar 06 09:07 PM | | Reed Thomas D. | Chief Science Officer | Mar 04 | Sale | 4.18 | 225,500 | 943,690 | 44,005 | Mar 06 09:07 PM | | ALVAREZ CESAR L | Director | Feb 19 | Option Exercise | 3.17 | 2,968 | 9,409 | 117,817 | Feb 21 04:46 PM | | Frank Steven | Director | Feb 12 | Option Exercise | 3.17 | 2,968 | 9,409 | 195,225 | Feb 14 04:41 PM | | Reed Thomas D. | Chief Science Officer | Feb 07 | Option Exercise | 3.17 | 2,969 | 9,412 | 96,280 | Feb 11 04:57 PM | | LIFFMAN JOEL D | SVP, Finance | Jan 04 | Sale | 7.03 | 3,725 | 26,187 | 85,541 | Jan 04 06:46 PM | | Walsh Robert F. III | SVP, Energy & Fine Chem. | Jan 03 | Sale | 7.07 | 4,058 | 28,692 | 5,708 | Jan 04 06:46 PM | | Reed Thomas D. | Chief Science Officer | Jan 03 | Sale | 7.07 | 2,944 | 20,816 | 79,537 | Jan 04 06:47 PM | | Perez Jeffrey Thomas | SVP, IP Affairs | Jan 03 | Sale | 7.07 | 3,514 | 24,846 | 18,789 | Jan 04 06:48 PM | | Lehr Donald P. | Chief Legal Officer | Jan 03 | Sale | 7.07 | 3,832 | 27,094 | 34,183 | Jan 04 06:48 PM | | Sterling Rick L. | Chief Financial Officer | Jan 03 | Sale | 7.07 | 3,514 | 24,846 | 80,873 | Jan 04 06:46 PM | | Sabzevari Helen | President, Precigen, Inc. | Jan 03 | Sale | 7.07 | 3,832 | 27,094 | 22,532 | Jan 04 06:46 PM | | Nimrodi Nir | Chief Business Officer | Jan 03 | Sale | 7.07 | 4,058 | 28,692 | 5,708 | Jan 04 06:45 PM | | Reed Thomas D. | Chief Science Officer | Dec 31 | Sale | 6.36 | 30,000 | 190,671 | 72,715 | Jan 03 05:56 PM | | LIFFMAN JOEL D | SVP, Finance | Oct 15 | Sale | 14.59 | 79,000 | 1,152,808 | 79,500 | Oct 17 07:51 PM | | Sabzevari Helen | President, Precigen, Inc. | Jul 18 | Sale | 14.54 | 8,402 | 122,165 | 16,598 | Jul 19 06:03 PM |
|
